Astellas Pharma US, Inc., has received approval to market tacrolimus (Prograf canadian) as an immunosuppressant to prevent organ rejection in patients who have received a heart transplant. Prograf is also used to treat patients undergoing kidney and liver transplantation.
The FDA’s review was based on one U.S. study and one European study. Tacrolimus generic is available in approximately 70 countries.